Study guide

3.6 Thyroid Disorders & Anemia in Pregnancy

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

3.6 Thyroid Disorders & Anemia in Pregnancy

Key Takeaways Explain This Topic AI

Patients with pre-existing hypothyroidism require a 20 to 30 percent levothyroxine increase as early as the fifth week of pregnancy, targeting TSH below 2.5 mIU/L in the first trimester and below 3.0 mIU/L thereafter.

Propylthiouracil is preferred in the first trimester to avoid methimazole embryopathy, and therapy is switched to methimazole in the second trimester to avoid PTU-induced fulminant hepatic necrosis.

Thioamides are titrated to keep maternal free T4 at or slightly above the upper limit of the non-pregnant reference range, using the lowest effective dose to avoid fetal goitrous hypothyroidism.

Plasma volume expands 45 to 50 percent while red cell mass rises only 20 to 30 percent, producing physiologic hemodilution that nadirs at 24 to 28 weeks.

A serum ferritin below 30 ng/mL confirms iron deficiency before red cell indices change, and alternate-day oral iron dosing lowers hepcidin peaks and improves fractional absorption.

Last updated: September 2026

  • Thyroid Disorders in Pregnancy
  • Gestational Thyroid Physiology

Maternal thyroid hormone production increases by 30% to 50% during pregnancy to meet maternal and embryonic metabolic demands. Two key mechanisms drive this adaptation:

Human Chorionic Gonadotropin (hCG): Shares structural homology (alpha subunit) with TSH. High first-trimester hCG levels weakly stimulate the TSH receptor, resulting in a physiologic surge in free thyroxine (FT4) and a transient physiologic suppression of serum TSH (nadir at 10–12 weeks).

Estrogen-Induced Thyroxine-Binding Globulin (TBG): Estrogen stimulates hepatic TBG synthesis and impairs TBG clearance, doubling total circulating TBG levels. Consequently, total T4 and total T3 concentrations increase by 50%, while free T4 (FT4) remains the active, physiologically regulated fraction.

Overt Hypothyroidism

Defined as an elevated serum TSH with a decreased FT4 concentration, or a serum TSH >10 mIU/L regardless of FT4 level.

Maternal-Fetal Consequences: Untreated overt hypothyroidism is linked to increased rates of early spontaneous abortion, preeclampsia, gestational hypertension, placental abruption, low birth weight, and irreversible deficits in fetal neuropsychological and cognitive development.

Pharmacotherapy: Levothyroxine (T4) is the drug of choice (starting dose 1.6 mcg/kg/day for overt disease). In individuals with pre-existing hypothyroidism, pregnancy increases levothyroxine requirements by 20% to 30% as early as the fifth week of gestation. Patients should be counseled to preemptively increase their dosage (e.g., taking two additional tablets per week, or increasing the daily dose by 25%–30%) upon a positive pregnancy test and immediately contact their provider.

Target TSH Thresholds:

  • First trimester: <2.5 mIU/L (or lower reference limit of population normal, ~0.1–2.5 mIU/L)
  • Second and third trimesters: <3.0 mIU/L (or 0.2–3.0 mIU/L)

Surveillance: Monitor serum TSH every 4 to 6 weeks during the first half of pregnancy until stable, and at least once per trimester thereafter.

Hyperthyroidism

Overt hyperthyroidism (suppressed TSH with elevated FT4 or FT3) occurs in 0.2% of pregnancies, most commonly caused by Graves' disease (autoimmune stimulation of TSH receptors by thyroid-stimulating immunoglobulin [TSI]).

Risks: Thyroid storm, heart failure, preeclampsia, fetal hydrops, intrauterine growth restriction, and neonatal Graves' disease (due to transplacental crossing of TSI).

Pharmacotherapy Protocol:

First Trimester: Propylthiouracil (PTU) is the preferred thioamide (dose: 50–150 mg PO three times daily). Methimazole is avoided during organogenesis because of associated teratogenic embryopathy ( aplasia cutis , choanal atresia, and esophageal atresia).

Second and Third Trimesters: Switch from PTU to Methimazole (dose: 5–20 mg PO daily) starting at the beginning of the second trimester to avoid PTU-induced severe maternal fulminant hepatic necrosis.

Target Range: Titrate thioamides to maintain maternal free T4 at or slightly above the upper limit of the normal non-pregnant range using the lowest effective dose, thereby preventing fetal drug exposure and fetal goitrous hypothyroidism.

  • Anemia in Pregnancy: Hemodilution vs. Iron Deficiency
  • Physiologic Hemodilution ("Physiologic Anemia")

During normal pregnancy, maternal intravascular plasma volume expands by 45% to 50% , whereas erythrocyte mass expands by only 20% to 30% in response to erythropoietin. This disproportionate fluid expansion results in physiologic hemodilution, characterized by decreased blood viscosity, enhanced uteroplacental perfusion, and a physiologic drop in hemoglobin and hematocrit that nadirs in the late second trimester (24–28 weeks).

  • Diagnostic Criteria for Anemia (CDC & ACOG Standards)
  • First Trimester: Hemoglobin <11.0 g/dL (Hematocrit <33%)
  • Second Trimester: Hemoglobin <10.5 g/dL (Hematocrit <32%)
  • Third Trimester: Hemoglobin <11.0 g/dL (Hematocrit <33%)
  • Postpartum: Hemoglobin <10.0 g/dL (Hematocrit <30%)
  • Iron Deficiency Anemia (IDA)

Iron deficiency accounts for over 75% of non-physiologic anemias in pregnancy. Fetal iron demands take precedence across the placental transfer gradient; maternal iron stores deplete first.

Diagnostic Biomarkers:

Serum Ferritin: The single most sensitive and specific test for total body iron depletion in pregnancy. A serum ferritin <30 ng/mL confirms iron deficiency anemia even before red blood cell indices change.

Complete Blood Count Indices: Low mean corpuscular volume ( MCV <80 fL , microcytosis), low mean corpuscular hemoglobin concentration (MCHC, hypochromia), and elevated red blood cell distribution width ( RDW >14.5% ).

Oral Iron Therapy:

Dose: 60 to 120 mg of elemental iron daily (e.g., ferrous sulfate 325 mg tablet provides 65 mg elemental iron; ferrous fumarate 325 mg provides 106 mg elemental iron; ferrous gluconate 325 mg provides 36 mg elemental iron).

Patient Education: Take on an empty stomach with a source of vitamin C (ascorbic acid, e.g., orange juice) to enhance enteric iron absorption. Avoid concurrent ingestion with calcium supplements, antacids, dairy, tea, or coffee, which bind iron and block absorption.

Alternate-Day Dosing: Recent clinical trials demonstrate that alternate-day iron dosing (e.g., 60–100 mg elemental iron every other morning) induces lower hepcidin peaks, improves fractional iron absorption, and substantially mitigates gastrointestinal side effects (nausea, constipation, abdominal cramping).

Intravenous Iron Therapy:

Indications: Severe intolerance or non-adherence to oral iron, severe malabsorption syndromes (e.g., post-Roux-en-Y gastric bypass, celiac disease, inflammatory bowel disease), or severe late-gestation anemia (Hb <8.0–9.0 g/dL at >34 weeks) where rapid repletion prior to delivery is imperative.

Agents: Intravenous iron sucrose, ferric carboxymaltose, or ferumoxytol provide complete store replenishment within 1 to 2 infusions with low risk of anaphylactoid reactions.